Àrees de recerca

• New therapeutic strategies for pseudomyxoma peritonei (PMP)
• Generation of patient-derived preclinical models to provide a platform for evaluating novel therapies for different types of cancer

Educació

• PhD in Cellular Biology, Immunology and Neurosciences, University of Barcelona, 2010.
• MSc in Cellular Biology, Immunology and Neurosciences, University of Barcelona, 2006.
• BSc in Biology, University Pompeu Fabra, 2004.

Experiència professional

• 2020-2023: Research Associate, Stem Cells & Cancer Group, VHIO, Barcelona, Spain.
• 2015- 2020: Senior Postdoctoral Researcher, Stem Cells & Cancer Group, VHIO, Barcelona, Spain.
• 2014-2015: Senior Postdoctoral Researcher, Transcriptional Regulation of Gene Expression Group, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
• 2010-2014: Postdoctoral Researcher, Molecular Neurotherapy and Imaging Laboratory, Massachusetts General Hospital-Harvard University Medical School, Boston, USA.
• 2005-2010: PhD student, Gene and Viral Therapy Group, IDIBELL-Catalan Institute of Oncology (ICO), L’Hospitalet de Llobregat, Barcelona, Spain.
• 2004-2005: Technical Assistant, FERRER INTERNACIONAL, S.A, Barcelona, Spain.

Premis i distincions

• Investigador: Marie Curie Action grant (Individual fellowship) from European Commission (2017-2019). Budget: 173.000€.
• Postdoctoral Researcher: Beatriu de Pinós postdoctoral fellowship from AGAUR (2015-2017). Budget: 91.022€.
• Postdoctoral Researcher: Postdoctoral training fellowship from MINECO from Plan Estatal de Investigación Científica y Técnica y de Innovación (2014-2015).
• Postdoctoral Researcher: Fulbright postdoctoral fellowship from Ministerio de Educación of Spain (2012-2013).
• PhD student: Official IDIBELL fellowship from Fundación privada Institut d’Investigació Biomédica de Bellvitge (IDIBELL) (2006-2008).

Projectes de recerca amb independència i lideratge

• Colorectal cancer – Stratification of Therapies through Adaptive Responses (CRC-STARS). FINANCIAL ENTITY: Cancer Research UK Beatson Institute; Asociación Española Contra el Cáncer. Duration: 2025-2029. co-PIs: Jordi Martínez-Quintanilla and Héctor G. Palmer.
• Drug-loaded nanobots for transmucosal delivery to mucinous tumours (MucOncoBots) FINANCIAL ENTITY: European Research Council (ERC). Duration: 01/10/2023 – 31/04/2025. co-PIs: Jordi Martínez-Quintanilla and Héctor G. Palmer.
• Patient-Derived Organoids 2.0: Recapitulating stromal and immune microenvironment in annotated organoid platforms for advancing towards personalized cancer treatment. FINANCIAL ENTITY: CIBERONC. Duration: 2021-2024. Co-PIs: Jordi Martínez-Quintanilla and Héctor G. Palmer. (Consortium Coordinator: Patricia Pérez).
• Tumor microenvironment-derived factors in localized colon cancer: clinical impact and therapeutic implications. FINANCIAL ENTITY: Fundación de la Asociación Española Contra el Cáncer (AECC). Duration: 2020-2024. Co-PIs: Jordi Martínez-Quintanilla and Héctor G. Palmer (Coordinator: Andrés Cervantes).
• Accelerator Award. Pseudomyxoma peritonei: building a European multicentric cohort to accelerate new therapeutic perspectives. FINANCIAL ENTITY: Cancer Research UK (CRUK), Asociación Española contra el Cancer (AECC) & Associazione Italina per la Ricerca sul Cancro (AIRC). Duration: 2019-2024. Co-PIs: Jordi Martínez-Quintanilla and Héctor G. Palmer. (Consortium Coordinator: Marcello Deraco).
• Therapeutic inhibition of the oncogenicWnt/beta-catenin pathway in mismatch repair deficient hypermutant tumors. FINANCIAL ENTITY: European Commission. Marie Skłodowska-Curie actions – Research Fellowship Programme. Marie Curie (704319). Duration: 2017-2019. Investigator: Jordi Martínez-Quintanilla.

Contractes no competitius com a investigador

Investigador

• Evaluation of Petosemtamab in combination with BRAF inhibitors in CRC. FUNDING COMPANY: Merus. Duration: 28/10/2025-28/10/2027. Co-Investigator VHIO: Jordi Martínez-Quintanilla and Héctor G. Palmer. Budget: 464.000 €.
• Identification of T cell receptors targeting hotspot mutations in common driver oncogenes from tumor specimens of mismatch repair proficient colorectal carcinoma patients. FUNDING COMPANY: AstraZeneca. Duration: 14/11/2024-14/11/2027. Co-Investigator VHIO: Jordi Martínez-Quintanilla and Héctor G. Palmer. Budget: 690.900 €.
• Therapeutic efficacy of extrachromosomal DNA (ecDNA) targeted therapies (ecDTx) in colorectal cancer tumors. FUNDING COMPANY: Boundless Bio. Duration: 17/09/2024-16/03/2026. Co-Investigator VHIO: Jordi Martínez-Quintanilla and Héctor G. Palmer. Budget: 211.500 €.
• Discovering the mechanisms of resistance to BRAF inhibitor Compound Ia in colorectal cancer. FUNDING COMPANY: Roche. Duration: 23/05/2024-23/05/2026. Co-Investigator VHIO: Jordi Martínez-Quintanilla and Héctor G. Palmer. Budget: 162.192 €.
• Therapeutic targeting of CLDN1 pathway in iCCA and CRC. FUNDING COMPANY: Alentis Therapeutics. Duration: 01/09/2023-01/09/2025. Co-Investigator VHIO: Jordi Martínez-Quintanilla and Héctor G. Palmer. Budget: 605.622 €.
• Therapeutic targeting the Hippo Pathway in colorectal cancer. FUNDING COMPANY: Ikena Oncology. Duration: 01/10/2022-01/10/2024. Co-Investigator VHIO: Jordi Martínez-Quintanilla and Héctor G. Palmer. Budget: 322.500 €.
• Evaluate the efficacy of CDK2/9 inhibitor fadraciclib and PLK-1 inhibitor cyc140 in CRC. FUNDING COMPANY: Cyclacel Pharmaceutical. Duration: 01/01/2022-01/01/2024. Co-Investigator VHIO: Jordi Martínez-Quintanilla and Héctor G. Palmer. Budget: 150.300 €.

Transferència de tecnologia i innovació

• European patent Case P60104. Inventors: Piergiorgio FT. Pettazzoni, Héctor G. Palmer, Jordi Martínez Quintanilla, Florian Renner. Title: Novel use of quinazolinone compound for the treatment of cancer. Filling date: 03/04/2025. Patent-holding entity: My contribution as a co-inventor on this patent involved designing the preclinical experiments that were essential for evaluating the potential of this new therapeutic compound.

Supervisió i mentoria

2025-date: Co-direction. PhD Student Pablo Arráez: Characterization of HIVEP2 in drug persister cancer cells. Universidad Autónoma de Barcelona (UAB).

2019-2024: Co-direction. PhD Student Alex Mur Espinosa: Role of HIVEP2 in drug-tolerant persister cancer cells and tumor recurrence. Presentation date: 17/12/2024. Universidad de Barcelona. Excellent Cum Laude.

2025: Co-direction. MSc Student Pablo Arráez: HIVEP2 induces chemoresistance in organoids derived from CRC patients. Presentation date: 09/07/2025. Universidad Autónoma de Barcelona (UAB).

2018: Co-direction. MSc Maddalen Otaegi Ugartemendia: Hypermutant colorectal cancer: efficient generation of VCMsh2LoxP/LoxP mice- derived intestinal cancer organoids biobank. Presentation date: 05/07/2018. Universidad de Barcelona (UB).

2015: Scientific supervisor. MSc Lidia Sánchez-Moral: Regulation of Hippo pathway target genes by ZEB1 in colorectal carcinoma. 2015. Universidad de Barcelona (UB).

2014: Scientific supervisor. Final degree project Derek He: The use of inducible oncolytic adenoviruses delivered by stem cells to treat GBMs. Harvard Medical School.

2014: Scientific supervisor. Final degree project Amina Kunnummal: Engineered oncolytic viruses for the treatment of brain tumors. Harvard Medical School.

2011: Scientific supervisor. Final degree project Ana Mosquera: Molecular pathway of the synergism between HSVtk-GCV system and TRAIL. Harvard Medical School.

Marcs de recerca

2020-to date PMPnet group

2020-to date Grupo Español de Cirugía Oncológica Peritoneal (GECOB)

2020-to date Sociedad Española de Oncología Quirúrgica (SEOQ)

2021-date CIBERONC research group (PDO 2.0 project 2021-2024 and Immune4ALL 2022 to date)

2019-2024 EuroPMP COST Action

2018-2022 EuroPDX

Experiència internacional

2010-2014 Postdoctoral Researcher / Massachusetts General Hospital-Harvard University Medical School

Conferències i reunions

• Martínez-Quintanilla, J. Advancing precision oncology and systemic targeted therapies for patients with Pseudomyxoma Peritonei. XI Reunión Internacional GECOP & IX Congreso Nacional SEOQ. Grupo español de cirugía oncológica Peritoneal & Sociedad española de Oncología Quirúrgica. 2026. PRESENTACIÓN ORAL ONLINE.
• Martínez-Quintanilla, J. Role of BRAFV600E in hypermutant CRC. CRC-STARS 1st Annual Meeting. CRUK Scotland Institute. 2026. United Kingdom. PRESENTACIÓN ORAL.
• Martínez-Quintanilla, J. Advancing precision oncology and systemic targeted therapies for patients with Pseudomyxoma Peritonei. V Mesa Redonda de Investigación en Pseudomyxoma Peritonea. Hospital Universitario Fundación Jiménez Díaz. 2025. PRESENTACIÓN ORAL.
• Martínez-Quintanilla, J. Precision oncology and systemic targeted therapy in Pseudomyxoma Peritonei. X Reunión Internacional GECOP & VIII Congreso Nacional SEOQ. Grupo español de cirugía oncológica Peritoneal & Sociedad española de Oncología Quirúrgica. 2024. PRESENTACIÓN ORAL.
• Martínez-Quintanilla, J. Precision oncology and systemic targeted Therapy in Pseudomyxoma Peritonei. EuroPDX 10th Anniversary Symposium. Institut Curie. 2023. France. PRESENTACIÓN ORAL.
• Martínez-Quintanilla, J. Systemic targeted Therapy in Pseudomyxoma Peritonei. IDIBAPS Gastrointestinal and PancreaticOncology seminars. Centre Esther Koplowitz (IDIBAPS). 2023. PRESENTACIÓN ORAL.
• Martínez-Quintanilla, J. Targeted Therapy in Pseudomyxoma Peritonei. The 13th PSOGI International Congress on Peritoneal Surface Malignancies. 2023. Italy. PRESENTACIÓN ORAL.
• Martínez-Quintanilla, J. Targeted Therapy in Pseudomyxoma Peritonei. JORNADA DE CIRUGÍA ONCOLÓGICA PERITONEAL. Complex Hospitalari Universitari Moisès 2023. Spain. PRESENTACIÓN ORAL.
• Martínez-Quintanilla, J. Pre-clinical models reveal new therapeutic oportunities for Pseudomyxoma Peritonei. III Mesa Redonda de Investigación en Pseudomyxoma Peritoneal. Hospital Universitario Fundación Jiménez Díaz. 2023. PRESENTACIÓN ORAL.
• Martínez-Quintanilla, J. Deciphering the role of oncogenic BRAF in mismatch repair deficient colorectal tumors. ACRCelerate Autumn Workshop. Vall d’Hebron Institute of Oncology (VHIO). 2022. PRESENTACIÓN ORAL.
• Martínez-Quintanilla, J. Generación de un biobanco de PDOs y PDXs de pacientes con PMP. II Mesa Redonda de Investigación en Pseudomyxoma Peritoneal. Instituto Maimónides de Investigación Biomédica (IMIBIC). 2022. PRESENTACIÓN ORAL ONLINE.
• Martínez-Quintanilla, J. Establishment of PMP-PDX models for testing new therapeutic estrategies for PMP patients. EuroPMP COST monthly seminars. EuroPMP COST. 2021. PRESENTACIÓN ORAL ONLINE.
• Camara J; Martínez-Quintanilla J; Palmer H. Ultrasonography of spontaneous intestine tumor and spleen evaluation in MSH2LC transgenic mice. 14th Molecular Imaging Meeting. European Society of Molecular Imaging (ESMI). 2019. United Kingdom. PRESENTACIÓN POSTER.
• Martínez-Quintanilla, J; Shah, K. Therapeutic efficacy and fate of bimodal engineered stem cells in mice models of malignant brain tumors. 4th World Federation of Neuro-Oncology. Society for Neuro-Oncology. 2013. United States of America. PRESENTACIÓN POSTER.
• Hingtgen, S; Martinez-Quintanilla, J; Shah, K. Real-time assessment of glioblastoma surgical resection and recurrence using multimodality imaging. 17th Annual Scientific Meeting. Soc Neuro Oncol (SNO). 2012. PRESENTACIÓN POSTER.
• Martínez-Quintanilla, J; Alemany, R. In vivo positive selection of TK-transduced cells increases the efficacy of pancreatic cancer suicide gene therapy. V Meeting of the Spanish Society of Gene and Cell Therapy. 2009. Spain. PRESENTACIÓN POSTER.
• Gros, A; Martínez-Quintanilla, J; Cascallo, M. Increasing the potency of oncolytic adenovirus by introducing a gain of function mutation that enhances adenovirus cell release. 16^th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy. 2008. Belgium. PRESENTACIÓN POSTER.
• Martínez-Quintanilla, J; Alemany, R. Cell competition, a new approach to cancer gene therapy. XIV Annual Congress of the European Society of Gene Therapy. Greece. PRESENTACIÓN POSTER.

Publicacions seleccionades

Publicacions científiques

• Renner F; Eckmann J; Handl C; Wichmann J; Schnetzler G; Kratochwil NA; Keshelava N; Ros J; Élez E; Vergés J; Chicote I; Martínez-Quintanilla J; Palmer HG; Pettazzoni P. 2025. Mosperafenib, a novel paradox breaker BRAF inhibitor with potent preclinical activity in BRAF mutated colorectal cancer. MOL CANCER THER. https://doi.org/10.1158/1535-7163.MCT-25-0562
• Centonze A; Roura AJ; Novillo-Font M; Giordano C; Hernando-Momblona X; Llanses M; Prats P; Sevillano M; Cabot D; Novell M; Pabst G; Andersch F; Cañellas-Socias A; Zhang C; Giakoumakis NN; Sparks H; Dunsby C; Colombelli J; Fernández-Barral A; Sancho E; Stephan-Otto Attolini C; Muñoz A; Barbachano A; Palmer HG; Martínez-Quintanilla J; Zuber J; Blaj C; Quintana E; Cortina C; Marti-Renom MA; Batlle E. 2025. A plastic EMP1⁺ to LGR5⁺ cell state conversion as a bypass to KRAS-G12D pharmacological inhibition in metastatic colorectal cancer. CANCER DISCOV. https://doi.org/10.1158/2159-8290.CD-25-0679
• Linares-Blanco J; Chicote I; Ros J; et al.; Seoane J; Martínez-Quintanilla J. 2025. Transcriptomic Signature Reveals Sensitivity to Tubulin Inhibitors in Colon Cancer. bioRxiv. https://doi.org/10.1101/2025.01.14.633026
• Varinelli L; Di Bella M; Guaglio M; et al.; Gariboldi M; Martínez-Quintanilla J. 2024. A combinatorial culture strategy to develop pseudomyxoma peritonei organoid models. J SURG ONCOL. 130(6), pp.1213-1224. https://doi.org/10.1002/jso.27850
• Villarejo Campos P; Vázquez-Borrego MC; Martínez-Quintanilla J; et al.; Arjona-Sánchez A. 2024. Undetectable circulating tumor DNA confirms the inability of pseudomyxoma peritonei to systemic dissemination. EUR J SURG ONCOL. 50(7), pp.108395. https://doi.org/10.1016/j.ejso.2024.108395
• Martínez-Quintanilla J; Cabot D; Sabia D; Arqués O; Vergés J; Chicote I; Bijelic L; Cabellos L; Alcántara AM; Ramos Bernadó MI; Barrios P; Crusellas Maña O; Palacio LM; Serrano JAC; Barriuso J; Jiménez JJ; Muñoz Torres PM; Nonell L; Flores R; Medico E; Guaglio M; Ros J; Élez E; Tabernero J; Aziz O; Deraco M; Palmer HG. 2024. Precision oncology and systemic targeted therapy in Pseudomyxoma Peritonei. CLIN CANCER RES. 30(18), pp.4082-4099. https://doi.org/10.1158/1078-0432.CCR-23-4072
• Cuesta-Borras E; Salvans C; Arqués O; et al.; Puig I; Martínez-Quintanilla J. 2023. DPPA3-HIF1α axis controls colorectal cancer chemoresistance by imposing a slow cell-cycle phenotype. CELL REPORTS. 42(8), pp.112927. https://doi.org/10.1016/j.celrep.2023.112927
• Chicote I; Martínez-Quintanilla J; Cámara JA; Palmer HG. 2023. Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer. J VIS EXP. 192. https://doi.org/10.3791/64629
• Kiyokawa J; Kawamura Y; Ghouse SM; Suryadevara CM; Choi SH; Pei Y; Martínez-Quintanilla J; Sayour EJ; Mitchell DA; Wakimoto H; Shah K. 2021. Modification of extracellular matrix enhances oncolytic adenovirus immunotherapy in glioblastoma. CLIN CANCER RES. 27(3), pp.889-902. https://doi.org/10.1158/1078-0432.CCR-20-2400
• Puig I; Tenbaum SP; Chicote I; Arqués O; Martínez-Quintanilla J; Cuesta-Borrás E; Ramírez L; Gonzalo P; Soto A; Aguilar S; Eguizabal C; Caratù G; Prat A; Argilés G; Landolfi S; Casanovas O; Serra V; Villanueva A; Arroyo AG; Terracciano L; Nuciforo P; Seoane J; Recio JA; Vivancos A; Dienstmann R; Tabernero J; Palmer HG. 2018. TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence. J CLIN INVEST. 128(9), pp.3887-3905. https://doi.org/10.1172/JCI96393
• Heidari P; Kunawudhi A; Martínez-Quintanilla J; Szretter A; Shah K; Mahmood U. 2018. Somatostatin Receptor Type 2 as a Radiotheranostic PET Reporter Gene for Oncologic Interventions. THERANOSTICS. 8(12), pp.3380-3391. https://doi.org/10.7150/thno.24017
• Choi SH; Stuckey DW; Pignatta S; Reinshagen C; Khalsa JK; Roozendaal N; Martínez-Quintanilla J; Tamura K; Keles E; Shah K. 2017. Tumor resection recruits effector T cells and boosts therapeutic efficacy of encapsulated stem cells expressing INFbeta in glioblastomas. CLIN CANCER RES. 23(22), pp.7047-7058. https://doi.org/10.1158/1078-0432.CCR-17-0077
• Bagci-Onder T; Du W; Figueiredo JL; Martínez-Quintanilla J; Shah K. 2015. Targeting breast to brain metastatic tumours with death receptor ligand expressing therapeutic stem cells. BRAIN. 138(Pt 6), pp.1710-1721. https://doi.org/10.1093/brain/awv094
• Martínez-Quintanilla J; He D; Wakimoto H; Alemany R; Shah K. 2015. Encapsulated stem cells loaded with hyaluronidase-expressing oncolytic virus for brain tumor therapy. MOL THER. 23(1), pp.108-118. https://doi.org/10.1038/mt.2014.204
• Duebgen M; Martínez-Quintanilla J; Tamura K; Hingtgen S; Redjal N; Wakimoto H; Shah K. 2014. Stem cells loaded with multimechanistic oncolytic herpes simplex virus variants for brain tumor therapy. JNCI-J NATL CANCER I. 106(6): dju090. https://doi.org/10.1093/jnci/dju090
• Hingtgen S; Figueiredo JL; Farrar C; Duebgen M; Martínez-Quintanilla J; He D; Shah K. 2013. Real-time multi-modality imaging of glioblastoma tumor resection and recurrence. J NEURO-ONCOL. 111(2), pp.153-161. https://doi.org/10.1007/s11060-012-1008-z
• Martínez-Quintanilla J; Bhere D; Heidari P; He D; Mahmood U; Shah K. 2013. Therapeutic efficacy and fate of bimodal engineered stem cells in malignant brain tumors. STEM CELLS. 31(8), pp.1706-1714. https://doi.org/10.1002/stem.1355
• Rojas JJ; Guedan S; Searle PF; Martínez-Quintanilla J; Gil-Hoyos R; Alcayaga-Miranda F; Cascallo M; Alemany R. 2010. Minimal RB-responsive E1A promoter modification to attain potency, selectivity and transgenes-arming capacity in oncolytic adenoviruses. MOLECULAR THERAPY. 18(11), pp.1960-1971. https://doi.org/10.1038/mt.2010.173
• García-Castro J; Alemany R; Cascalló M; Martínez-Quintanilla J; Arriero MM; Lassaletta A; Madero L; Ramírez M. 2010. Treatment of metastatic neuroblastoma with systemic oncolytic virotherapy delivered by autologous mesenchymal stem cells: an exploratory study. CANCER GENE THERAPY. 17(7), pp.476-483. https://doi.org/10.1038/cgt.2010.4
• Rojas JJ; Cascallo M; Guedan S; Gros A; Martínez-Quintanilla J; Hemminki A; Alemany R. 2009. A modified E2F-1 promoter improves the efficacy to toxicity ratio of oncolytic adenoviruses. GENE THERAPY. 16(12), pp.1441-1451. https://doi.org/10.1038/gt.2009.103
• Martínez-Quintanilla J; Cascallo M; Gros A; Fillat C; Alemany R. 2009. Positive selection of gene-modified cells increases the efficacy of pancreatic cancer suicide gene therapy. MOL CANCER THER. 8(11), pp.3098-3107. https://doi.org/10.1158/1535-7163.MCT-09-0350
• Martínez-Quintanilla J; Cascallo M; Fillat C; Alemany R. 2009. Antitumor therapy based on cellular competition. HUMAN GENE THERAPIES. 20(7), pp.728-738. https://doi.org/10.1089/hum.2008.144
• Gros A; Martínez-Quintanilla J; Puig C; Guedan S; Mollevi DG; Alemany R; Cascallo M. 2008. Bioselection of a gain of function mutation that enhances adenovirus 5 release and improves its antitumoral potency. CANCER RESEARCH. 68(21), pp.8928-8937. https://doi.org/10.1158/0008-5472.CAN-08-1145

Revisions científiques

• Martínez-Quintanilla J; Seah S; Chua M; Shah K. 2019. Oncolytic Viruses: Overcoming Translational Challenges. J CLIN INVEST. 129(4), pp.1407-1418. https://doi.org/10.1172/JCI122287

Carta de resposta a la revista

Martínez-Quintanilla J; Shah K. 2014. Response Re: Stem cells loaded with multimechanistic oncolytic herpes simplex virus variants for brain tumor therapy. JNCI-J NATL CANCER I. 107(1), pp.370. https://doi.org/10.1093/jnci/dju370